Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or
metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the
patients enrolled:
- Cohort I: Patients previously treated with one taxane containing regimen.
- Cohort II: Patients previously treated with a platinum based but non-taxane containing
regimen.
- Cohort III: Patients previously treated with both a chemotherapy regimen and one
EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) compound.
Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound.
Prior treatment with a VEGFR (vascular endothelial growth factor receptor) inhibitor compound
is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR
inhibitor.